vs
Side-by-side financial comparison of Snap-on (SNA) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 2.0× Snap-on). Zoetis runs the higher net margin — 25.3% vs 21.3%, a 3.9% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs 2.7%). Zoetis produced more free cash flow last quarter ($732.0M vs $254.6M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 2.0%).
Snap-on Incorporated is an American designer, manufacturer, and marketer of high-end tools and equipment for professional use in the transportation industry, including the automotive, heavy duty, equipment, marine, aviation, and railroad industries. Headquartered in Kenosha, Wisconsin, since 1930, Snap-on also distributes lower-end tools under the brand name Blue-Point. Their primary competitors include Matco, Mac Tools, and Cornwell Tools.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
SNA vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $260.7M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 27.8% | 31.9% |
| Net Margin | 21.3% | 25.3% |
| Revenue YoY | 2.7% | 3.0% |
| Net Profit YoY | 1.0% | 3.8% |
| EPS (diluted) | $4.94 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.1B | $2.4B | ||
| Q2 24 | $1.2B | $2.4B | ||
| Q1 24 | $1.2B | $2.2B |
| Q4 25 | $260.7M | $603.0M | ||
| Q3 25 | $265.4M | $721.0M | ||
| Q2 25 | $250.3M | $718.0M | ||
| Q1 25 | $240.5M | $631.0M | ||
| Q4 24 | $258.1M | $581.0M | ||
| Q3 24 | $251.1M | $682.0M | ||
| Q2 24 | $271.2M | $624.0M | ||
| Q1 24 | $263.5M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 27.8% | 31.9% | ||
| Q3 25 | 29.4% | 37.0% | ||
| Q2 25 | 28.0% | 36.7% | ||
| Q1 25 | 27.7% | 36.5% | ||
| Q4 24 | 27.9% | 31.6% | ||
| Q3 24 | 28.4% | 36.6% | ||
| Q2 24 | 29.9% | 33.0% | ||
| Q1 24 | 28.9% | 34.1% |
| Q4 25 | 21.3% | 25.3% | ||
| Q3 25 | 22.5% | 30.0% | ||
| Q2 25 | 21.4% | 29.2% | ||
| Q1 25 | 21.2% | 28.4% | ||
| Q4 24 | 21.7% | 25.1% | ||
| Q3 24 | 22.0% | 28.6% | ||
| Q2 24 | 23.1% | 26.4% | ||
| Q1 24 | 22.4% | 27.4% |
| Q4 25 | $4.94 | $1.37 | ||
| Q3 25 | $5.02 | $1.63 | ||
| Q2 25 | $4.72 | $1.61 | ||
| Q1 25 | $4.51 | $1.41 | ||
| Q4 24 | $4.83 | $1.29 | ||
| Q3 24 | $4.70 | $1.50 | ||
| Q2 24 | $5.07 | $1.37 | ||
| Q1 24 | $4.91 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.3B |
| Total Assets | — | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $1.5B | $2.1B | ||
| Q2 25 | $1.5B | $1.4B | ||
| Q1 25 | $1.4B | $1.7B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $3.3B | ||
| Q3 25 | $5.8B | $5.4B | ||
| Q2 25 | $5.7B | $5.0B | ||
| Q1 25 | $5.5B | $4.7B | ||
| Q4 24 | $5.4B | $4.8B | ||
| Q3 24 | $5.5B | $5.2B | ||
| Q2 24 | $5.3B | $5.0B | ||
| Q1 24 | $5.1B | $5.1B |
| Q4 25 | — | $15.5B | ||
| Q3 25 | $8.4B | $15.2B | ||
| Q2 25 | $8.2B | $14.5B | ||
| Q1 25 | $8.1B | $14.1B | ||
| Q4 24 | $7.9B | $14.2B | ||
| Q3 24 | $8.0B | $14.4B | ||
| Q2 24 | $7.8B | $14.2B | ||
| Q1 24 | $7.7B | $14.3B |
| Q4 25 | — | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 0.21× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.1M | $893.0M |
| Free Cash FlowOCF − Capex | $254.6M | $732.0M |
| FCF MarginFCF / Revenue | 20.8% | 30.7% |
| Capex IntensityCapex / Revenue | 1.1% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.03× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $268.1M | $893.0M | ||
| Q3 25 | $277.9M | $938.0M | ||
| Q2 25 | $237.2M | $486.0M | ||
| Q1 25 | $298.5M | $587.0M | ||
| Q4 24 | $293.5M | $905.0M | ||
| Q3 24 | $274.2M | $951.0M | ||
| Q2 24 | $301.1M | $502.0M | ||
| Q1 24 | $348.7M | $595.0M |
| Q4 25 | $254.6M | $732.0M | ||
| Q3 25 | $258.0M | $805.0M | ||
| Q2 25 | $217.5M | $308.0M | ||
| Q1 25 | $275.6M | $438.0M | ||
| Q4 24 | $275.4M | $689.0M | ||
| Q3 24 | $253.8M | $784.0M | ||
| Q2 24 | $277.9M | $370.0M | ||
| Q1 24 | $326.9M | $455.0M |
| Q4 25 | 20.8% | 30.7% | ||
| Q3 25 | 21.8% | 33.5% | ||
| Q2 25 | 18.6% | 12.5% | ||
| Q1 25 | 24.3% | 19.7% | ||
| Q4 24 | 23.1% | 29.7% | ||
| Q3 24 | 22.3% | 32.8% | ||
| Q2 24 | 23.7% | 15.7% | ||
| Q1 24 | 27.8% | 20.8% |
| Q4 25 | 1.1% | 6.7% | ||
| Q3 25 | 1.7% | 5.5% | ||
| Q2 25 | 1.7% | 7.2% | ||
| Q1 25 | 2.0% | 6.7% | ||
| Q4 24 | 1.5% | 9.3% | ||
| Q3 24 | 1.8% | 7.0% | ||
| Q2 24 | 2.0% | 5.6% | ||
| Q1 24 | 1.9% | 6.4% |
| Q4 25 | 1.03× | 1.48× | ||
| Q3 25 | 1.05× | 1.30× | ||
| Q2 25 | 0.95× | 0.68× | ||
| Q1 25 | 1.24× | 0.93× | ||
| Q4 24 | 1.14× | 1.56× | ||
| Q3 24 | 1.09× | 1.39× | ||
| Q2 24 | 1.11× | 0.80× | ||
| Q1 24 | 1.32× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SNA
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
